JP2022550353A5 - - Google Patents
Info
- Publication number
- JP2022550353A5 JP2022550353A5 JP2022519331A JP2022519331A JP2022550353A5 JP 2022550353 A5 JP2022550353 A5 JP 2022550353A5 JP 2022519331 A JP2022519331 A JP 2022519331A JP 2022519331 A JP2022519331 A JP 2022519331A JP 2022550353 A5 JP2022550353 A5 JP 2022550353A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- methyl
- naphthyridine
- trans
- pyrimidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019108296 | 2019-09-26 | ||
| CNPCT/CN2019/108296 | 2019-09-26 | ||
| PCT/CN2020/117487 WO2021057853A1 (en) | 2019-09-26 | 2020-09-24 | Aza-quinoline compounds and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022550353A JP2022550353A (ja) | 2022-12-01 |
| JP2022550353A5 true JP2022550353A5 (cg-RX-API-DMAC7.html) | 2023-08-22 |
| JP7763753B2 JP7763753B2 (ja) | 2025-11-04 |
Family
ID=75166744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022519331A Active JP7763753B2 (ja) | 2019-09-26 | 2020-09-24 | アザキノリン化合物およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12544374B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4034535B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7763753B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102889562B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN114746414B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020355837B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3150284A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK4034535T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3067468T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL291499B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021057853A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK4034535T3 (da) | 2019-09-26 | 2026-04-07 | Novartis Ag | Aza-quinolinforbindelser og anvendelser deraf |
| AR123185A1 (es) * | 2020-08-10 | 2022-11-09 | Novartis Ag | Compuestos y composiciones para inhibir ezh2 |
| AR128015A1 (es) * | 2021-12-16 | 2024-03-20 | Transthera Sciences Nanjing Inc | Inhibidor de cdk9 y uso del mismo |
| CN117384153A (zh) * | 2022-07-12 | 2024-01-12 | 上海赛岚生物科技有限公司 | 一类甲基转移酶抑制剂及其用途 |
| CN118515653B (zh) * | 2024-07-23 | 2024-12-10 | 西湖制药(杭州)有限公司 | 一种ezh2特异性抑制剂及其制备方法和用途 |
| CN118598873B (zh) * | 2024-08-07 | 2024-11-19 | 艾斯拓康生物医药(天津)有限公司 | 一种手性的氮杂-喹啉类化合物的制备方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2779780A (en) | 1955-03-01 | 1957-01-29 | Du Pont | 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation |
| EP0647450A1 (en) | 1993-09-09 | 1995-04-12 | BEHRINGWERKE Aktiengesellschaft | Improved prodrugs for enzyme mediated activation |
| JP2002532415A (ja) | 1998-12-16 | 2002-10-02 | ワーナー−ランバート・カンパニー | Mek阻害剤による関節炎の治療 |
| AU7349801A (en) | 2000-07-19 | 2002-01-30 | Warner Lambert Co | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| CA2478065C (en) | 2002-03-08 | 2013-01-08 | Eisai Co. Ltd. | Macrocyclic compounds useful as pharmaceuticals |
| SG2013013339A (en) | 2002-03-13 | 2014-12-30 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| MX2008002114A (es) | 2005-07-21 | 2008-04-17 | Ardea Biosciences Inc | Inhibidores de n-(arilamino)-sulfonamida de mek. |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| BRPI0816769A2 (pt) | 2007-09-12 | 2016-11-29 | Hoffmann La Roche | combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso |
| WO2009055730A1 (en) | 2007-10-25 | 2009-04-30 | Genentech, Inc. | Process for making thienopyrimidine compounds |
| US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
| WO2014155301A1 (en) | 2013-03-26 | 2014-10-02 | Piramal Enterprises Limited | Substituted bicyclic compounds as inhibitors of ezh2 |
| MX375970B (es) | 2014-12-23 | 2025-03-06 | Novartis Ag | Compuestos de triazolopirimidina y usos de los mismos. |
| TW201708210A (zh) | 2015-06-30 | 2017-03-01 | 葛蘭素史克智慧財產(第二)有限公司 | Zeste同源物2增強子之抑制劑 |
| JP2019524872A (ja) | 2016-06-20 | 2019-09-05 | ノバルティス アーゲー | 癌の治療に有用なイミダゾピリミジン化合物 |
| US10689378B2 (en) | 2016-06-20 | 2020-06-23 | Novartis Ag | Triazolopyridine compounds and uses thereof |
| MX2019004950A (es) | 2016-10-28 | 2019-09-26 | Icahn School Med Mount Sinai | Composiciones y metodos para tratar el cancer mediado por el potenciador del homologo zeste 2. |
| DK4034535T3 (da) | 2019-09-26 | 2026-04-07 | Novartis Ag | Aza-quinolinforbindelser og anvendelser deraf |
-
2020
- 2020-09-24 DK DK20868772.3T patent/DK4034535T3/da active
- 2020-09-24 JP JP2022519331A patent/JP7763753B2/ja active Active
- 2020-09-24 IL IL291499A patent/IL291499B2/en unknown
- 2020-09-24 US US17/632,990 patent/US12544374B2/en active Active
- 2020-09-24 AU AU2020355837A patent/AU2020355837B2/en active Active
- 2020-09-24 EP EP20868772.3A patent/EP4034535B1/en active Active
- 2020-09-24 WO PCT/CN2020/117487 patent/WO2021057853A1/en not_active Ceased
- 2020-09-24 ES ES20868772T patent/ES3067468T3/es active Active
- 2020-09-24 CA CA3150284A patent/CA3150284A1/en active Pending
- 2020-09-24 KR KR1020227011716A patent/KR102889562B1/ko active Active
- 2020-09-24 CN CN202080067448.9A patent/CN114746414B/zh active Active
-
2025
- 2025-11-21 US US19/396,743 patent/US20260076968A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2413727C2 (ru) | Производные пиразола и их применение в качестве ингибиторов рецепторных тирозинкиназ | |
| RU2477723C2 (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
| JP2023538159A5 (cg-RX-API-DMAC7.html) | ||
| AU2013300344B2 (en) | N2,N4-bis(4-(piperazine-1-yl)phenyl)pirimidine-2,4-diamine derivative or pharmaceutically acceptable salt thereof, and composition containing same as active ingredient for preventing or treating cancer | |
| JP2023123854A5 (cg-RX-API-DMAC7.html) | ||
| JP2010517946A5 (cg-RX-API-DMAC7.html) | ||
| RU2472797C2 (ru) | ПРОИЗВОДНЫЕ 2-[(2-(ФЕНИЛАМИНО)-1Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)АМИНО]БЕНЗАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ IGF-1R ДЛЯ ЛЕЧЕНИЯ РАКА | |
| JP2021529812A5 (cg-RX-API-DMAC7.html) | ||
| IL291499B2 (en) | Aza-quinoline compounds and uses thereof | |
| JP2021512059A5 (cg-RX-API-DMAC7.html) | ||
| CN114430739A (zh) | Egfr抑制剂、组合物及其制备方法 | |
| JP2013056930A5 (cg-RX-API-DMAC7.html) | ||
| IL291590B2 (en) | Novel substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof | |
| JP2020524719A5 (cg-RX-API-DMAC7.html) | ||
| RU2019136279A (ru) | C5 -Анилинохиназолиновые соединения и их использование в лечении рака | |
| RU2007134396A (ru) | Химические соединения | |
| JP2019535744A5 (cg-RX-API-DMAC7.html) | ||
| JPWO2020017587A5 (cg-RX-API-DMAC7.html) | ||
| JP2015531773A (ja) | スルファモイル−アリールアミド及びb型肝炎の治療のための薬剤としてのその使用 | |
| JP2010530885A5 (cg-RX-API-DMAC7.html) | ||
| HRP20140975T1 (hr) | Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze | |
| RU2013113733A (ru) | Фармацевтически активные соединения в качестве ингибиторов axl | |
| RU2017122062A (ru) | Соединение 2-аминопиримидина и фармацевтическая композиция и применение данного соединения | |
| RU2744168C1 (ru) | Новое пиримидиновое производное, обладающее эффектом ингибирования роста раковых клеток, и содержащая его фармацевтическая композиция | |
| RU2009125916A (ru) | Соединения-ингибиторы фосфоинозитид 3-киназы и способы применения |